Author:
Aras Oguz AZ.,Patel Apar S.,Satchell Emma K.,Serniak Nicholas J.,Byrne Raphael M.,Cagir Burt
Abstract
Abstract
Introduction
Despite advances in medical therapy, approximately 33% of Crohn’s disease (CD) patients will need surgery within 5 years after initial diagnosis. Several surgical approaches to CD have been proposed including small bowel resection, strictureplasty, and combined surgery with resection plus strictureplasty. Here, we utilize the American College of Surgeons (ACS) national surgical quality registry (NSQIP) to perform a comprehensive analysis of 30-day outcomes between these three surgical approaches for CD.
Methods
The authors queried the ACS-NSQIP database between 2015 and 2020 for all patients undergoing open or laparoscopic resection of small bowel or strictureplasty for CD using CPT and IC-CM 10. Outcomes of interest included length of stay, discharge disposition, wound complications, 30-day related readmission, and reoperation.
Results
A total of 2578 patients were identified; 87% of patients underwent small bowel resection, 5% resection with strictureplasty, and 8% strictureplasty alone. Resection plus strictureplasty (combined surgery) was associated with the longest operative time (p = 0.002). Patients undergoing small bowel resection had the longest length of hospital stay (p = 0.030) and the highest incidence of superficial/deep wound infection (44%, p = 0.003) as well as the highest incidence of sepsis (3.5%, p = 0.03). Small bowel resection was found to be associated with higher odds of wound complication compared to combined surgery (OR 2.09, p = 0.024) and strictureplasty (1.9, p = 0.005).
Conclusion
Our study shows that various surgical approaches for CD are associated with comparable outcomes in 30-day related reoperation and readmission, or disposition following surgery between all three surgical approaches. However, small bowel resection displayed higher odds of developing post-operative wound complications.
Publisher
Springer Science and Business Media LLC
Reference42 articles.
1. Gajendran M, Loganathan P, Catinella AP, Hashash JG (2018) A comprehensive review and update on Crohn’s disease. Dis Mon 64(2):20–57. https://doi.org/10.1016/j.disamonth.2017.07.001
2. (2006) ‘American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease’. https://doi.org/10.1016/j.gastro.2006.01.048
3. Sinagra E, Orlando A, Mocciaro F, Criscuoli V, Oliva L, Maisano S, Giunta M, La Seta F, Solina G, Rizzo AG, Leone A, Tomasello G, Cappello F, Cottone M (2018) Clinical course of severe colitis: a comparison between Crohns Disease and ulcerative colitis. J Biol Regul Homeost Agents 32(2):415–423
4. Bonovas S et al (2016) Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol 14(10):1385–1397e10. https://doi.org/10.1016/j.cgh.2016.04.039
5. Frolkis AD et al (2013) Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology 145(5):996–1006. https://doi.org/10.1053/j.gastro.2013.07.041